TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: Spine Patient Outcomes Research Trial (SPORT): A Multicenter Trial for Spinal Stenosis (SpS)
Brief Summary: This study tests the effectiveness of different treatments for the three most commonly diagnosed conditions of the lower backbone (lumbar spine). The purpose is to learn which of two commonly prescribed treatments (surgery and nonsurgical therapy) works better for specific types of low back pain. Low back pain is one of the most widely experienced health problems in the United States and the world. It is the second most frequent condition, after the common cold, for which people see a doctor or lose days from work.

In this part of the study, we will treat patients with spinal stenosis (a narrowing of spaces in the backbone that results in pressure on the spinal cord and/or nerve roots) with a type of surgery known as posterior decompressive laminectomy or with nonsurgical methods. This study does not cover the cost of treatment.


Options:
A: Changes in health-related quality of life as measured by the SF-36 health status questionnaire (Baseline, 6 wks, 3 and 6 mos, Annually thereafter)
B: Medical Outcomes Study 36-item Short Form Health Survey (Measured at Month 24)
C: Changes in health-related quality of life as measured by the SF-36 health status questionnaire (Baseline, 6 wks, 3 and 6 mos, Annually thereafter)
D: Mean Change in VAS (Baseline and 6 weeks prior to cross-over); Mean Change in ODI (Baseline and 6 weeks prior to cross-over); Mean Change in VAS (Baseline and 26 weeks After ESI to mild cross-over); Mean Change in ODI (Baseline and 26 weeks After ESI to mild cross-over)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Self-Efficacy and High-Intensity Strength Training to Improve Postoperative Rehabilitation of Hip Fracture Patients
Brief Summary: This project will assess the effectiveness of a novel approach involving patient education and strength training to improve functional recovery after a hip fracture. Participants will be randomly assigned to one of two study groups. One group (control group) will receive standard medical care. The other group will participate in a program of patient education and strength training, including an at-home walking program.


Options:
A: We will use a composite endpoint by these two instruments: Clinical Dementia Rating Scale (CDR), and the 10 words memory task from the Consortium to Establish a Registry for Alzheimer's Disease battery (CERAD) (4 and 12 months)
B: N/A
C: Change in the performance-based Short physical performance battery (SPPB) (Change 5 days - 3 weeks, change 5 days - 3 months, change 5 days - 12 months after surgery)
D: functional recovery (baseline, end of nursing home admission)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Pharmacologic Relapse Prevention for Alcoholic Smokers
Brief Summary: This study will compare the long-term use of bupropion (Wellbutrin) and placebo for reducing the rate of smoking relapse in recovering alcoholics who achieved initial abstinence from smoking with nicotine patch therapy. The study will also determine the cessation rate in the 8th week of treatment among recovering alcoholics using a nicotine patch. The patch dose is projected to serve as a 100-percent replacement.


Options:
A: Smoking behavior (after 5 hrs abstinence)
B: Number of Participants Completing Continuous Four-week Abstinence From Smoking Between the 8-week and 11-week Post Quit Day Visits (Period between 8-week and 11-week visits post target Quit Day)
C: 4 week Continuous Quit Rate ( 4 week CQR ) for Weeks 9 -12.
D: Will bupropion reduce relapse to smoking compared to placebo (52 weeks and 76 weeks)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Pharmacologic Relapse Prevention for Alcoholic Smokers
Brief Summary: This study will compare the long-term use of bupropion (Wellbutrin) and placebo for reducing the rate of smoking relapse in recovering alcoholics who achieved initial abstinence from smoking with nicotine patch therapy. The study will also determine the cessation rate in the 8th week of treatment among recovering alcoholics using a nicotine patch. The patch dose is projected to serve as a 100-percent replacement.


Options:
A: Percentage of Participants With 4-week Continuous Abstinence (CA) (Week 9 through Week 12)
B: Will bupropion reduce relapse to smoking compared to placebo (52 weeks and 76 weeks)
C: Number of Responders With Carbon Monoxide (CO) Confirmed 4-week Continuous Quit Rate (CQR) for Last 4 Weeks of Treatment (Trtmt) (weeks 9 through 12)
D: Percentage of Participants With Carbon Monoxide (CO) Confirmed 10-Week Continuous Abstinence (CA) From Smoking (Week 15 - 24)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Pharmacologic Relapse Prevention for Alcoholic Smokers
Brief Summary: This study will compare the long-term use of bupropion (Wellbutrin) and placebo for reducing the rate of smoking relapse in recovering alcoholics who achieved initial abstinence from smoking with nicotine patch therapy. The study will also determine the cessation rate in the 8th week of treatment among recovering alcoholics using a nicotine patch. The patch dose is projected to serve as a 100-percent replacement.


Options:
A: 7 Day Point Prevalence of Cigarette Abstinence (6-month follow up); 7 Day Point Prevalence of Cigarette Abstinence (Week 8)
B: Cigarette use (8 weeks)
C: Percent Treatment Sessions Attended (52 weeks)
D: Will bupropion reduce relapse to smoking compared to placebo (52 weeks and 76 weeks)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Pharmacologic Relapse Prevention for Alcoholic Smokers
Brief Summary: This study will compare the long-term use of bupropion (Wellbutrin) and placebo for reducing the rate of smoking relapse in recovering alcoholics who achieved initial abstinence from smoking with nicotine patch therapy. The study will also determine the cessation rate in the 8th week of treatment among recovering alcoholics using a nicotine patch. The patch dose is projected to serve as a 100-percent replacement.


Options:
A: Quit Rate (4 months)
B: continuous abstinence (CAR) from weeks 9 to 12 of treatment (3 months)
C: Will bupropion reduce relapse to smoking compared to placebo (52 weeks and 76 weeks)
D: Seven-day point prevalence smoking abstinence at end of trial (abstinence based on self-reported smoking abstinence verified by CO levels < 10 ppm) (9 weeks)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Pharmacologic Relapse Prevention for Alcoholic Smokers
Brief Summary: This study will compare the long-term use of bupropion (Wellbutrin) and placebo for reducing the rate of smoking relapse in recovering alcoholics who achieved initial abstinence from smoking with nicotine patch therapy. The study will also determine the cessation rate in the 8th week of treatment among recovering alcoholics using a nicotine patch. The patch dose is projected to serve as a 100-percent replacement.


Options:
A: 4 week Continuous Quit Rate ( 4 week CQR ) for Weeks 9 -12.
B: Treatment Satisfaction (End of treatment (seven weeks after baseline))
C: Biochemically/pharmacologically-confirmed 12-month continuous abstinence as evidenced by self-reports of nonsmoking status in all interviews (i.e., at 3, 6, and 12 months) (12 months)
D: Will bupropion reduce relapse to smoking compared to placebo (52 weeks and 76 weeks)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: N/A
Brief Summary: To determine whether warfarin or lovastatin alone or in combination retarded the progression of atherosclerotic plaques in the carotid arteries of high risk individuals with asymptomatic carotid stenosis. Also, to determine if a full scale trial was feasible.


Options:
A: Stroke and death (4 years)
B: Rate of Change in Mean Posterior-wall Carotid Intima-media Thickness (cIMT) (Baseline, 6 months, 12 months, 18 months, and 24 months)
C: N/A
D: absolute changes in carotid intima-media thickness from baseline to final visit (12 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: N/A
Brief Summary: To determine whether warfarin or lovastatin alone or in combination retarded the progression of atherosclerotic plaques in the carotid arteries of high risk individuals with asymptomatic carotid stenosis. Also, to determine if a full scale trial was feasible.


Options:
A: Change of intima media thickness of the common carotid artery on the leading side of the neck.
B: Restenosis of the treated infrapopliteal artery (12 months); Major amputation (12 months); Clinical driven-target lesion revascularization (12 months); Major cardiovascular events (12 months)
C: N/A
D: Number of patients with symptomatic or asymptomatic VTE (28 days)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: N/A
Brief Summary: To determine whether warfarin or lovastatin alone or in combination retarded the progression of atherosclerotic plaques in the carotid arteries of high risk individuals with asymptomatic carotid stenosis. Also, to determine if a full scale trial was feasible.


Options:
A: N/A
B: Number of Participants Who Are Alive and Free of Invasive Mechanical Ventilation or ECMO Through Day 28 (Day 1 to Day 28 (28 days))
C: To estimate the prevalence of asymptomatic deep venous thrombosis and pulmonary emboli in obese patients undergoing bariatric surgery. (2 years)
D: a composite of acute VTE, arterial thrombosis, treatment with ECMO, or all-cause mortality (30 days from enrollment)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women
Brief Summary: The purpose of this study is to evaluate the effects of low-dose aspirin and vitamin E in primary prevention of cardiovascular disease and cancer in apparently healthy women.


Options:
A: Number of Participants With Composite of Total Mortality, Disabling Stroke, Serious Bleeding, or Cardiac Arrest in Patients Warranting Therapy for AF. (From date of enrollment until time-to-first event over a median follow-up of 48.5 months.)
B: The primary endpoint of the study is defined as AF burden between 3 to 12 months after first AF ablation (12 months)
C: First Occurrence of a Severe Cardiovascular Event (up to 11 years)
D: Number of Participants With Major Cardiovascular Events (a Combined Endpoint of Nonfatal Myocardial Infarction, Nonfatal Stroke, and Total Cardiovascular Death) (Average follow-up 10.1 years); Number of Participants With Cancer, Excluding Nonmelanoma Skin Cancer (Average follow-up 10.1 years)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women
Brief Summary: The purpose of this study is to evaluate the effects of low-dose aspirin and vitamin E in primary prevention of cardiovascular disease and cancer in apparently healthy women.


Options:
A: 7-item Juniper Asthma Control Questionnaire (ACQ) (6-months post-randomizaton)
B: asthma free days (12 weeks)
C: Number of Participants With Major Cardiovascular Events (a Combined Endpoint of Nonfatal Myocardial Infarction, Nonfatal Stroke, and Total Cardiovascular Death) (Average follow-up 10.1 years); Number of Participants With Cancer, Excluding Nonmelanoma Skin Cancer (Average follow-up 10.1 years)
D: Episodes of Poor Asthma Control (EPAC) From Diary Cards, According to Definition That Did Not Include Use of Beta-agonists as a Criterion (Baseline to 24 Weeks)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women
Brief Summary: The purpose of this study is to evaluate the effects of low-dose aspirin and vitamin E in primary prevention of cardiovascular disease and cancer in apparently healthy women.


Options:
A: Prostate cancer (Ongoing); Total cancer (Ongoing); Major cardiovascular events (Ongoing)
B: Number of Participants With Major Cardiovascular Events (a Combined Endpoint of Nonfatal Myocardial Infarction, Nonfatal Stroke, and Total Cardiovascular Death) (Average follow-up 10.1 years); Number of Participants With Cancer, Excluding Nonmelanoma Skin Cancer (Average follow-up 10.1 years)
C: Cardiovascular disease; Cancer
D: Retinal blood flow (in total 8x on 2 study days)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women
Brief Summary: The purpose of this study is to evaluate the effects of low-dose aspirin and vitamin E in primary prevention of cardiovascular disease and cancer in apparently healthy women.


Options:
A: The primary efficacy parameter was reduction in incident new vertebral fractures assessed by spinal radiographs (anterior-posterior and lateral) (3 years)
B: Incidence of invasive breast cancer; superiority of one of the therapies. (Time from randomization to the occurance of invasive breast cancer.)
C: Number of Participants With Major Cardiovascular Events (a Combined Endpoint of Nonfatal Myocardial Infarction, Nonfatal Stroke, and Total Cardiovascular Death) (Average follow-up 10.1 years); Number of Participants With Cancer, Excluding Nonmelanoma Skin Cancer (Average follow-up 10.1 years)
D: fractures (4 years)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women
Brief Summary: The purpose of this study is to evaluate the effects of low-dose aspirin and vitamin E in primary prevention of cardiovascular disease and cancer in apparently healthy women.


Options:
A: Episodes of Poor Asthma Control (EPAC) From Diary Cards, According to Definition That Did Not Include Use of Beta-agonists as a Criterion (Baseline to 24 Weeks)
B: Asthma Quality of Life Questionnaire (Baseline, 6 weeks, 3 months, 6 months)
C: asthma free days (12 weeks)
D: Number of Participants With Major Cardiovascular Events (a Combined Endpoint of Nonfatal Myocardial Infarction, Nonfatal Stroke, and Total Cardiovascular Death) (Average follow-up 10.1 years); Number of Participants With Cancer, Excluding Nonmelanoma Skin Cancer (Average follow-up 10.1 years)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: N/A
Brief Summary: To evaluate the feasibility of recruiting women of different socioeconomic status and minority groups and to determine whether these women could achieve and maintain a modified fat-eating pattern. The full-scale trial sought to determine whether a low-fat diet could decrease the incidence of cancer and coronary heart disease in postmenopausal women. The National Heart, Lung, and Blood Institute contributed funds over a three-year period to measure lipids, lipoproteins, and other cardiovascular disease risk factors.


Options:
A: body weight (prior to and after 4, 8, and 12 months of dieting)
B: Primary Outcome Measures Described Below (December 2011)
C: N/A
D: Hemoglobin A1c (22 weeks)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: N/A
Brief Summary: The primary objective was to assess whether long-term administration of antihypertensive therapy to elderly subjects with isolated systolic hypertension reduced the combined incidence of fatal and non-fatal stroke. The secondary objectives were to evaluate: the effect of long-term antihypertensive therapy on mortality from any cause in elderly people with isolated systolic hypertension; possible adverse effects of chronic use of antihypertensive drug treatment in this population; the effect of therapy on indices of quality-of-life; the natural history of isolated systolic hypertension in the placebo population.


Options:
A: Prevention of Type 2 Diabetes (2.4 years)
B: absolute changes in carotid intima-media thickness from baseline to final visit (12 months)
C: To demonstrate the effect of pactimibe versus placebo, when added to usual medical care, on the intima-media thickness (IMT) of the carotid arteries in subjects with heterozygous familial hypercholesterolemia (HeFH) and carotid atherosclerosis.
D: N/A

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: N/A
Brief Summary: The primary objective was to assess whether long-term administration of antihypertensive therapy to elderly subjects with isolated systolic hypertension reduced the combined incidence of fatal and non-fatal stroke. The secondary objectives were to evaluate: the effect of long-term antihypertensive therapy on mortality from any cause in elderly people with isolated systolic hypertension; possible adverse effects of chronic use of antihypertensive drug treatment in this population; the effect of therapy on indices of quality-of-life; the natural history of isolated systolic hypertension in the placebo population.


Options:
A: absolute changes in carotid intima-media thickness from baseline to final visit (12 months)
B: Morphological carotid plaque stabilization (Six months); Carotid plaque regression (12 months)
C: N/A
D: Assess the effects of rosuvastatin treatment on the change in the mean maximum intima media thickness (IMT) of the 12 vessel segments: the near & far walls of the CCA, the carotid bulb & the ICA

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: N/A
Brief Summary: The primary objective was to assess whether long-term administration of antihypertensive therapy to elderly subjects with isolated systolic hypertension reduced the combined incidence of fatal and non-fatal stroke. The secondary objectives were to evaluate: the effect of long-term antihypertensive therapy on mortality from any cause in elderly people with isolated systolic hypertension; possible adverse effects of chronic use of antihypertensive drug treatment in this population; the effect of therapy on indices of quality-of-life; the natural history of isolated systolic hypertension in the placebo population.


Options:
A: N/A
B: Analysis of incidence of thromboembolic events in patients with Sars-CoV-2 (1 month)
C: Hierarchical composite endpoint composed of mortality, number of days alive, number of days in the hospital and number of days with oxygen therapy at the end of 30 days. (In 30 days)
D: a composite of acute VTE, arterial thrombosis, treatment with ECMO, or all-cause mortality (30 days from enrollment)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS)
Brief Summary: To determine if supplements of vitamin C, vitamin E, beta-carotene, and B-vitamins (a combination of folic acid, vitamins B6 and B12) reduce risk of major cardiovascular events in high risk women with a prior history of atherosclerotic cardiovascular disease. The trial is a companion to the Women's Health Study (WHS), a primary prevention trial of vitamin E and aspirin in a low risk population of women.


Options:
A: all-type cancer (excluding non-melanoma skin cancers) (4 years)
B: Cardiovascular disease; Cancer
C: Number of Participants With Prostate Cancer (Every six months for 7 to 12 years depending on when the participant was randomized.)
D: fractures (4 years)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS)
Brief Summary: To determine if supplements of vitamin C, vitamin E, beta-carotene, and B-vitamins (a combination of folic acid, vitamins B6 and B12) reduce risk of major cardiovascular events in high risk women with a prior history of atherosclerotic cardiovascular disease. The trial is a companion to the Women's Health Study (WHS), a primary prevention trial of vitamin E and aspirin in a low risk population of women.


Options:
A: Change in mean carotid intima-media thickness; Change in maximum carotid intima-media thickness
B: Cardiovascular disease; Cancer
C: Major fatal and non fatal ischemic cardiovascular events; Cancer any kind except for basal cell skin carcinoma
D: Change in Clinical Dementia Rating Scale (CDR) (Change from baseline in CDR at month 9, 18, 27)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS)
Brief Summary: To determine if supplements of vitamin C, vitamin E, beta-carotene, and B-vitamins (a combination of folic acid, vitamins B6 and B12) reduce risk of major cardiovascular events in high risk women with a prior history of atherosclerotic cardiovascular disease. The trial is a companion to the Women's Health Study (WHS), a primary prevention trial of vitamin E and aspirin in a low risk population of women.


Options:
A: N/A
B: Composite of all cause death, non-fatal acute myocardial infarction, acute hospitalization for unstable angina pectoris, and of non-fatal thromboembolic stroke (infarction) (During follow-up, 1.5-5 years)
C: Cardiovascular disease; Cancer
D: 1 or more adenomas (For aspirin: follow-up years 1-3; For folate: follow-up years 1-3 and years 4-8)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS)
Brief Summary: To determine if supplements of vitamin C, vitamin E, beta-carotene, and B-vitamins (a combination of folic acid, vitamins B6 and B12) reduce risk of major cardiovascular events in high risk women with a prior history of atherosclerotic cardiovascular disease. The trial is a companion to the Women's Health Study (WHS), a primary prevention trial of vitamin E and aspirin in a low risk population of women.


Options:
A: Cellular and Humoral Immune Response (12 weeks)
B: Outcomes assessed will be based on the ongoing ocular examination and historical data that will be obtained at each visit. The visual acuity data and the photographic documentation of the two diseases will be of particular importance. (5 years)
C: A combination of CVD mortality non fatal MI and Stoke at a 4 year follow up.
D: Cardiovascular disease; Cancer

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS)
Brief Summary: To determine if supplements of vitamin C, vitamin E, beta-carotene, and B-vitamins (a combination of folic acid, vitamins B6 and B12) reduce risk of major cardiovascular events in high risk women with a prior history of atherosclerotic cardiovascular disease. The trial is a companion to the Women's Health Study (WHS), a primary prevention trial of vitamin E and aspirin in a low risk population of women.


Options:
A: Cardiovascular disease; Cancer
B: Major fatal and non fatal ischemic cardiovascular events; Cancer any kind except for basal cell skin carcinoma
C: Prostate cancer (Ongoing); Total cancer (Ongoing); Major cardiovascular events (Ongoing)
D: Development of Advanced AMD in People at Moderate to High Risk for Progression. (5 years of follow-up)

Answer: A